Eledon Reports Insulin Independence in Islet Transplant Patients Treated with Tegoprubart - BioTuesdays

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart ...

– All 12 patients in study (100%) achieved insulin independence, producing their own insulin and no longer requiring exogenous insulin therapy to manage their T1D

Release - Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine - Channelchek

Open the article to view the coverage from channelchek.com

Eledon reports insulin independence in islet transplant patients treated with tegoprubart - BioTuesdays

Eledon Pharmaceuticals (NASDAQ: ELDN) announced updated results from an investigator-initiated trial evaluating tegoprubart, its investigational anti-CD40L antibody, as part of a calcineurin inhibitor-free immunosuppression regimen in patients with type 1 diabetes undergoing allogeneic islet cell transplantation at the University of Chicago Medicine Transplant Institute. According to Eledon, all 12 patients in the study achieved insulin independ…

All 12 trial participants off external insulin: New tegoprubart data

New data presented this week at the American Diabetes Association’s (ADA) 86th Scientific Sessions in New Orleans shows incredible promise: all 12 participants in an islet cell transplant trial are off external insulin. These twelve individuals are in a study at the University of Chicago funded by Breakthrough T1D and others investigating the use of tegoprubart, an investigational immunotherapy from Eledon Pharmaceuticals. Individuals in the cli…